Novartis Predicts Strong Sales Growth Amid Patent Challenges

Saturday, 2 November 2024, 02:54

Novartis, led by CEO Vas Narasimhan, anticipates a sales growth of at least 5% annually, positioning itself to handle patent expiration effectively. With promising drugs like Entresto, Narasimhan expresses confidence in sustaining this growth trajectory. The company is committed to maintaining its innovative edge while navigating the pharmaceutical landscape.
Indiatimes
Novartis Predicts Strong Sales Growth Amid Patent Challenges

Novartis CEO's Confidence in Future Sales

In an interview with Finanz und Wirtschaft, CEO Vas Narasimhan stated that Novartis expects its annual sales to grow by at least 5% until 2028.

Key Strategies for Sustained Sales Growth

  • Narshimhan emphasizes the importance of a robust pipeline of multi-billion dollar medications.
  • Despite impending patent expirations on drugs like Entresto, he remains confident that growth will continue.
  • Focus on strategic acquisitions is part of the company’s plan to bolster its market position.

Although historical trends in the pharmaceutical industry have seen sales decline with patent expiries, Narasimhan assures that Novartis views this differently, citing a comprehensive strategy to mitigate risks.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Subscribe to our newsletter for the most accurate and current medical news. Stay updated and deepen your understanding of medical advancements effortlessly.

Subscribe